A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of participants with Adverse Events (AEs)

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with treatment-emergent adverse events (TEAEs)

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with Dose-Limiting Toxicity (DLT)

  Measured over: Up to 28 days after first dose

• Number of participants with laboratory abnormalities

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with vital sign abnormalities

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with Electrocardiogram (ECG) abnormalities

  Measured over: Up to 5 weeks after last dose of treatment

• Eastern Cooperative Oncology Group Performance Status (ECOG PS)

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalities

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants with Physical Examination (PE) abnormalities

  Measured over: Up to 5 weeks after last dose of treatment

• Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATL

  Measured over: Up to 2 years after last does of treatment

• Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based)

Changes Tremor has spotted